In hepatocellular carcinoma cells, PARP-1 activation inhibits the SP1 signaling pathway to promote cell proliferation, whereas PARP-1 inhibition enhances SP1-mediated expression of checkpoint proteins (e.g., p21 and p27), leading to cell cycle arrest at the G0/G1 phase. The gene discussed is SP1; the disease is hepatocellular carcinoma.